NovoPen Echo®: The first and only pen with a memory function and half-unit dosing

presentation of benefits of NovoPen Echo®

 

 

NovoPen Echo®: The first and only pen with a memory function and half-unit dosing

   

shadow
how NovoPen® is built

Needles are sold separately and may require a prescription in some states.
 



 

Who should use NovoPen Echo®?

NovoPen Echo® is an option for active patients who desire a memory function, precise and smaller half-unit dosing, or the ability to personalize their pens with a choice of skins.

chart comparing humapen luxura, NovoPen Echo® and autopen

Handles every day wear and tear

In a real-world study, NovoPen Echo® held up to everyday wear and tear, and was still accurate at every dose.1

thermometer icon

Hot and Colda
107.6ºF to 35.6ºF

vibration icon

Vibration

free-fall tested icon

Fallingb
(Free-fall tested)

aOnce opened, Novolog® PenFill® cartridges should be kept at temperatures below 86ºF for up to 28 days but should not be exposed to excessive heat or sunlight. See Prescribing Information for full storage guidelines.

bIf you drop the pen or suspect a problem, check the Insulin cartridge for damage; for example, cracks. Replace the cartridge with a new one if necessary.

 



 

Available in a variety of fun skins

Patients can customize their pen to make it their own.

Direct patients to the order center at NovoLogReach.com so they can order their favorite skin for free!

presentation of variety of fun NovoPen® skins
presentation of variety of fun NovoPen® skins


 

For use with NovoLog® 3-mL PenFill® cartridges and NovoTwist® or NovoFine® needles

NovoLog® PenFill®


 

Can be used with NovoTwist® or NovoFine® Needles

NovoTwist®– introducing the first single-twist needle

  • “Just Twist” injection needle with a bayonet fitting
  • Less time-consuming for patients to attach
  • Audible and tactile confirmatory click for correct attachment
  • Available for 32G Tip (5 mm) needles
mechanism of how NovoTwist® and NovoFine® needles work

NovoFine® Needles

  • NovoFine® needles fit all major insulin devices
  • NovoFine® 32G Tip with SuperFlow™ Technology designed to enhance flow rate and reduce dosing force when injecting
  • Little or no pain - A majority of patients using the NovoFine® 32G Tip needle experienced almost no painc
  • NovoLog® FlexPen® uses NovoFine® disposable needles, designed to help improve injection comfort
description of NovoFine® needles

cMulticenter, randomized, open-label, 2-period, crossover trial in insulin-treated patients with diabetes (type 1 or type 2). Patients were randomized to self administer insulin injections with one needle type followed by the alternative, each for 7 to 14 days. The 2 needle types used were NovoFine® 32-gauge tip x 6 mm and NovoFine® 30-gauge tip x 8 mm.2

 



 

NovoLog® FlexPen®, 3mL PenFill®,d and 10-mL vial: stable in storage

chart showing how NovoLog® FlexPen® is stable in storage

d3-mL PenFill® cartridge is available for NovoPen® Junior and NovoPen®.3
eFlexPen® and PenFill® cartridges in use (opened) must NOT be stored in the refrigerator.
fVials in use (opened) may be stored in the refrigerator until the label expiration date.
 


NovoPen® junior

What about NovoPen® Junior? NovoPen Echo® can used in place of NovoPen® Junior, which will no longer be available at pharmacies after March 14, 2013. NovoPen® and PenMate® will also be discontinued at this time. For more information, please call customer support at 1-800-727-6500.

 


Get insights from experts

Thought leaders talk about bolus insulin therapy, from the role of PPG control in helping to reach A1C goals to improving patient engagement.

Selected Important Safety Information

Contraindications

  • NovoLog® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® or one of its excipients. 

Warnings and Precautions

  • Never Share a NovoLog® FlexPen, NovoLog® FlexTouch®, PenFill® Cartridge, or PenFill® Cartridge Device Between Patients, even if the needle is changed. Patients using NovoLog® vials must never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens. 
  • Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. These changes should be made cautiously under close medical supervision and the frequency of blood glucose monitoring should be increased.

NovoLog® (insulin aspart injection) 100 U/mL Indications and Usage

NovoLog® (insulin aspart injection) 100 U/mL is an insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus. 

Important Safety Information

Contraindications

  • NovoLog® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® or one of its excipients. 

Warnings and Precautions

  • Never Share a NovoLog® FlexPen, NovoLog® FlexTouch®, PenFill® Cartridge, or PenFill® Cartridge Device Between Patients, even if the needle is changed. Patients using NovoLog® vials must never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens. 
  • Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. These changes should be made cautiously under close medical supervision and the frequency of blood glucose monitoring should be increased. 
  • Hypoglycemia is the most common adverse effect of insulin therapy. The timing of hypoglycemia may reflect the time-action profile of the insulin formulation. Glucose monitoring is recommended for all patients with diabetes and is particularly important for patients using external pump infusion therapy. 
  • To avoid medication errors and accidental mix-ups between NovoLog® and other insulin products, instruct patients to always check the insulin label before injection. 
  • Severe, life-threatening, generalized allergy, including anaphylaxis, may occur with insulin products, including NovoLog®
  • As with all insulins, NovoLog® use can lead to life-threatening hypokalemia, which then may cause respiratory paralysis, ventricular arrhythmia, and death.  Monitor potassium levels in patients at risk for hypokalemia and treat if indicated.
  • Fluid retention and heart failure can occur with concomitant use of thiazolidinediones (TZDs), which are PPAR-gamma agonists, and insulin, including NovoLog®. Patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of the TZD must be considered. 
  • Malfunction of the insulin pump or insulin infusion set or insulin degradation can rapidly lead to hyperglycemia and ketoacidosis. Patients using insulin infusion pump therapy must be trained to administer insulin by injection and have alternate insulin therapy available in case of pump failure. 

NovoLog® continuous subcutaneous infusion route (insulin pump): Do not mix NovoLog® with any other insulin or diluent. 

Adverse Reactions

  • Adverse reactions observed with NovoLog® include hypoglycemia, allergic reactions, local injection site reactions, lipodystrophy, rash, and pruritus. 

Use in Specific Populations

  • NovoLog® has not been studied in children with type 2 diabetes or in children with type 1 diabetes who are younger than 2 years of age. 
  • Like all insulins, NovoLog® requirements may be reduced in patients with renal impairment or hepatic impairment. These patients may require more frequent blood glucose monitoring and dose adjustments. 

Please click here for Prescribing Information.

 

References

  1. Kristensen CM, Lilleøre K. Dose accuracy and durability of a durable insulin pen before and after simulated lifetime use. Curr Med Res Opin. 2011;27(10):1877-1883.
  2. McKay M, Compion G, Lytzen L. A comparison of insulin injection needles on patients' perception of pain, handling, and acceptability: A randomized, open-label, crossover study in subjects with diabetes. Diabetes Tech. 2009;11(3)195-201.
  3. Data on file. Novo Nordisk, Inc., Plainsboro, NJ.